QUANTIFICATION USING ULTRAVIOLET SPECTROSCOPY METHOD AND IN VITRO STABILITY STUDY OF NANOVESICULAR SYSTEM CONTAINING PHYTIC ACID
Objective: The quantification of drug and stability of nanoparticulate delivery systems is one of the major apprehensions in biomedical applications. The present research work was attempted to quantify phytic acid by utilizing ultraviolet (UV) spectroscopy method and to evaluate the stability of nanovesicular (niosomes) system containing phytic acid.
Methods: Niosomes containing phytic acid were developed by thin-film hydration method. Nanoformulation was subjected to stability testing as per the International Council for Harmonisation (ICH) guidelines. The formulation was stored at 30Â°CÂ±2Â°C and 65%Â±5% RH, samples were withdrawn at 15th, 30th, 60th, 90th, 120th, and 180th day of analysis and examined for the integrity of vesicular/particle size, polydispersity index, zeta potential, and percent encapsulation efficiency.
Results: Prepared nanoformulation displayed a straight line (y=mx+c) equation of y=âˆ’0.0309x+1.0413. Optimized batch of niosomes, which was prepared including dicetylphosphate showed zeta potential value of âˆ’36Â±0.36. Stability study showed that prepared niosomal formulation was stable up to 180 days at room temperature.
Conclusion: Findings of the current research work suggested that UV spectroscopy method can be effectively used for the quantification of phytic acid and niosomal formulation of phytic acid. The formulation was found to be stable as per the ICH guidelines for stability testing.
2. Gupta KP, Singh J, Bharathi R. Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr Cancer 2003;46:66-72.
3. Pandey M, Gupta KP. Epigenetics, an early event in the modulation of gene expression by inositol hexaphosphate in ethylnitrosourea exposed mouse lungs. Nutr Cancer 2011;63:89-99.
4. Saad N, Esa NM, Ithnin H, Shafie NH. Optimization of optimum condition for phytic acid extraction from rice bran. Afr J Plant Sci 2011;5:168-75.
5. Patel J, Kevin G, Patel A, Raval M, Sheth N. Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies. Pharm Methods 2011;2:36-41.
6. Hemant KS, Raizaday A, Sivadasu P, Uniyal S, Kumar SH. Cancer nanotechnology: Nanoparticulate drug delivery for the treatement of cancer. Int J Pharm Pharm Sci 2014;7:40-6.
7. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: An illustrated review. J Control Release 2014;185:22-36.
8. Karna SC, Agrawal V, Alim M. Formulation approaches for sustained release dosage forms: A review. Asian J Pharm Clin Res 2015;8:46-53.
9. Escudero I, Geanta RM, Ruiz MO, Benito JM. Formulation and characterization of Tween 80/cholestherol niosomes modified with tri-n-octylmethylammonium chloride (TOMAC) for carboxylic acids entrapment. Colloids Surf A Physicochem Eng Asp 2014;461:167-77.
10. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 2008;353:233-42.
11. Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Oh DH, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 2009;377:1-8.
12. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS Pharmscitech 2010;11:1119-27.
13. Surya TS, Mothilal M, Damodharan N, Jaison D. Screening and optimization of valacyclovir niosomes by design of experiments. Int J App Pharm 2018;10:79-85.
14. Okore V, Attama A, Ofokansi K, Esimone C, Onuigbo E. Formulation and evaluation of niosomes. Indian J Pharm Sci 2011;73:323.
15. Asthana GS, Sharma PK, Asthana A. In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica 2016;2016:.
16. Mathew B, Rangapriya M, Rajendran N. Evaluation and stability studies of rifampicin loaded chitosan nanoparticle. World J Pharm Pharm Sci 2014;3:536-57.
17. Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, et al. Best practices in cancer nanotechnology: Perspective from NCI nanotechnology alliance. Clin Cancer Res 2012;18:3229-41.
18. Rezayat M. Preparation, characterization and stability investigation of chitosan nanoparticles loaded with the Echis carinatus snake venom as a novel delivery system. Arch Razi Institute 2015;70:269-77.
19. Ertekin ZC, Bayindir ZS, Yuksel N. Stability studies on piroxicam encapsulated niosomes. Curr Drug Deliv 2015;12:192-9.
20. Haug W, Lantzsch HJ. Sensitive method for the rapid determination of phytate in cereals and cereal products. J Sci Food Agric 1983;34:1423-6.
21. Acharya A, Kumar GB, Ahmed MG, Paudel S. Niosome-encapsulated clomipramine for transdermal controlled delivery. Int J Pharm Pharm Sci 2014;6:567-75.
22. Arya M, Tiwari P, Tripathi CB, Parashar P, Singh M, Sinha P, et al. Colloidal vesicular system of Inositol hexaphosphate to counteract DMBA induced dysregulation of markers pertaining to cellular proliferation/differentiation and inflammation of epidermal layer in mouse model. Mol Pharm 2017;14:928-39.
23. Kanoujia J, Singh M, Singh P, Parashar P, Tripathi CB, Arya M, et al. Genipin crosslinked soy-whey based bioactive material for atorvastatin loaded nanoparticles: Preparation, characterization and in vivo antihyperlipidemic study. RSC Adv 2016;6:93275-87.
24. Branch SK. Guidelines from the international conference on harmonisation (ICH). J Pharm Biomed Anal 2005;38:798-805.
25. Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS Pharmscitech 2008;9:740-7.
26. Bendas ER, Abdullah H, El-Komy MH, Kassem MA. Hydroxychloroquine niosomes: Anew trend in topical management of oral lichen planus. Int J Pharm 2013;458:287-95.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.